Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for the Evaluation of Neoadjuvant Treatment With Cabozantinib Pior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

NCT06377722 is registered in ClinicalTrials.gov with Fundacion Oncosur as lead sponsor.

NCT NCT06377722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06377722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for the Evaluation of Neoadjuvant Treatment With Cabozantinib Pior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Lead sponsor
Fundacion Oncosur
Phase
Phase 2
Overall status
Terminated
Start date
November 1, 2018
Completion date
August 9, 2022
Enrollment
18 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma metastatic, renal cell carcinoma stage iii, renal cell carcinoma stage iv